Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma

References

• Zhu YX, Braggio E, Shi C-X, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124:536–545.
   PubMed Web of Science ®Google Scholar
• Malek E, Abdel-Malek M, Jagannathan S, et al. Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia. 2017;31:645–653.
   PubMed Web of Science ®Google Scholar
• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983;1:359–367.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Phillips GL, Herzig RH, et al. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol. 2008;26:2240–2243.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Harousseau JL. New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplant. 2011;46:911–915.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome N. Engl J Med. 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Bayraktar UD, Bashir Q, Qazilbash M, et al. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:344–356.
   PubMed Web of Science ®Google Scholar
• Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer. 1982;45:86–94.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged≥ 70 years with multiple myeloma. Leukemia Lymphoma. 2012;53:118–122.
   PubMed Web of Science ®Google Scholar
• Shah N, Thall PF, Milton DR, et al. Phase I/II Trial of Lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma: updated results. Blood. 2016;128:2269–2269.
   Web of Science ®Google Scholar
• Shah N, Thall PF, Fox PS, et al. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015;29:1945.
   PubMed Web of Science ®Google Scholar
• Mark TM, Guarneri D, Forsberg P, et al. A phase I trial of high-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma. Biol Blood Marrow Transplant. 2017;23:930–937.
   PubMed Web of Science ®Google Scholar
• Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84:1035–1042.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999; 26(2 Suppl 7):3–21.
   Web of Science ®Google Scholar
• Wasserman T, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clinical Trials. 1980;4:3–6.
   Google Scholar
• Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer. 1996;32A Suppl 4:S5–S16.
   PubMed Web of Science ®Google Scholar
• Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm. 1997;54:787–800.
   PubMed Web of Science ®Google Scholar
• Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101–2112.
   PubMed Web of Science ®Google Scholar
• Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345.
   PubMed Web of Science ®Google Scholar
• Spencer A, Horvath N, Gibson J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 2005;35:971–977.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2002;30:769–775.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Meisenberg B, Reece DE, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004;10:473–483.
   PubMed Web of Science ®Google Scholar
• Bukowski R. Amifostine (Ethyol®): dosing, administration and patient management guidelines. Eur J Cancer. 1996;32:S46–S49.
   Google Scholar
• Schuchter LM. Guidelines for the administration of amifostine. Semin Oncol. 1996;23(4 Suppl 8):40–43.
   Web of Science ®Google Scholar
• Kyle R, Rajkumar S. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Fu P, Laughlin MJ, Zhang H. Comparison of survival times in a transplant study of hematologic disorders. Contemp Clin Trials. 2006;27:174–182.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc B Stat Methodol. 1972;34:187–220.
   Google Scholar
• De Souza C, Santini G, Marino G, et al. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. Braz J Med Biol Res. 2000;33:791–798.
   PubMed Web of Science ®Google Scholar
• Douay L, Hu C, Giarratana M-C, et al. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer. 1995;31:S14–S16.
   Google Scholar
• Shpall EJ, Stemmer S, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994;83:3132–3137.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Von Vangerow A, Fels L, et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation. Br J Cancer. 2001;84:313.
   PubMed Web of Science ®Google Scholar
• Campilho F, Campos A, Vaz C, et al. Amifostine (AMI) before high-dose melphalan (HDMel) and autologous hematopoietic stem cell transplantation (AHSCT) for patients with multiple myeloma (MM)-A case control analysis. Blood. 2001;98:201A.
   PubMedGoogle Scholar
• Cronin S, Uberti J, Ayash L, et al. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2004;33:S64.
   Web of Science ®Google Scholar
• Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:1031–1035.
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Johnson HR, Kaufman JL, et al. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:852–857.
   PubMed Web of Science ®Google Scholar
• Horsley P, Bauer JD, Mazkowiack R, et al. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2007;15:105–109.
   PubMed Web of Science ®Google Scholar
• Barasch A, Peterson DE, Tanzer JM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer. 1995;76:2550–2556.
   PubMed Web of Science ®Google Scholar
• Vokurka S, Bystřická E, Koza V, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT-results of a randomized multicentre study. Support Care Cancer. 2005;13:554–558.
   PubMed Web of Science ®Google Scholar
• Vokurka S, Bystrická E, Koza V, et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer. 2006;14:974–976.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chiang L, Selina N, et al. Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies. Support Care Cancer. 2004;12:526–530.
   PubMed Web of Science ®Google Scholar
• Dimopoulou I, Efstathiou E, Samakovli A, et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol. 2004;15:1250–1255.
   PubMed Web of Science ®Google Scholar
• Mougenot P, Pinguet F, Fabbro M, et al. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol 2004;53:503–512.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Becker PS, Gooley TA, et al. A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2016;51:67.
   PubMed Web of Science ®Google Scholar